Open AccessSNAI 2 and TWIST 1 in lymph node progression in early stages of NSCLC patients
Author(s) -
Emprou Camille,
Le Van Quyen Pauline,
Jégu Jérémie,
Prim Nathalie,
Weingertner Noëlle,
Guérin Eric,
Pencreach Erwan,
Legrain Michèle,
Voegeli AnneClaire,
Leduc Charlotte,
Mennecier Bertrand,
Falcoz PierreEmmanuel,
Olland Anne,
Santelmo Nicolas,
Quoix Elisabeth,
Massard Gilbert,
Guenot Dominique,
Chenard MariePierre,
BeauFaller Michèle
Publication year - 2018
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.1545
Subject(s) - vimentin , medicine , lymph node , cancer research , epithelial–mesenchymal transition , tumor progression , twist transcription factor , oncology , inducer , metastasis , cancer , immunohistochemistry , biology , gene , biochemistry
Lymph node metastasis is an important prognosis factor in non‐small cell lung cancer ( NSCLC ) patients. The aim of this study was to investigate the role of epithelial to mesenchymal transition ( EMT ) in lymph node progression in the early stages of NSCLC . We studied a retrospective cohort of 160 consecutive surgically treated NSCLC patients with available frozen tumor samples for expression of EMT markers ( CDH 1, CTNNB 1, CDH 2, and VIMENTIN ), inducers ( TGFB 1, c‐ MET , and CAIX ), and transcription factors ( EMT ‐ TF : SNAI 1, SNAI 2, ZEB 1, TWIST 1, and TWIST 2 ). Partial EMT was more frequent in N1‐2 (N+) vs N0 patients ( P < .01). TGFB 1 ( P = .02) as well as SNAI 2 ( P < .01) and TWIST 1 ( P = .04) were the most differentially expressed genes in N+ tumors. In this group, ZEB 1 was correlated with all EMT inducers and other EMT ‐ TF s were overexpressed depending on the inducers. CAIX was an independent prognostic factor for overall survival ( IC 95% HR : 1.10‐5.14, P = .03). Partial EMT is involved in lymph node progression of NSCLC patients and depends on the TGF β pathway. EMT ‐ TF s are differentially expressed depending on EMT inducers. CAIX might be a relevant prognostic marker in early stage NSCLC .